Compare Moderna, Inc. (MRNA) vs TeraWulf Inc (WULF) Price & Performance

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

WULF stock trades at $17.69, up 9.2% on the day amid a broader rally in AI infrastructure stocks. The technical picture is bearish with key support at $16 and resistance at $18. Fundamentally, the company reported a Q2 2026 net loss of $1.94 per share, missing estimates, while revenue trends are stable. Despite negative profitability metrics, analyst sentiment remains unanimously bullish with a $38.00 consensus price target, driven by expansion in high-performance computing capacity.

The outlook hinges on execution of its HPC growth strategy, but significant risks include persistent losses, high capital expenditure, and exposure to regulatory shifts. The stock offers high upside if operational targets are met, yet carries substantial volatility and execution risk for investors.